Literature DB >> 11746362

Akt activity in presenilin 1 wild-type and mutation transfected human SH-SY5Y neuroblastoma cells after serum deprivation and high glucose stress.

M Vestling1, B Wiehager, H Tanii, R F Cowburn.   

Abstract

The majority of early-onset familial Alzheimer disease cases are caused by mutations in the genes encoding presenilin 1 (PS1) and presenilin 2 (PS2). Presenilin mutations have been hypothesised to cause Alzheimer disease either by altering amyloid precursor protein metabolism or by increasing the vulnerability of neurons to undergo death by apoptosis. We showed previously that PS1 exon 9 deletion (PS1 DeltaE9) and L250S mutations predispose SH-SY5Y neuroblastoma cells to high glucose stress-induced apoptosis and that the anti-apoptotic effect of insulin-like growth factor I (IGF-I) is compromised by these mutations. The present study investigates whether the susceptibility of PS1 mutation transfected SH-SY5Y cells to undergo apoptosis is likely due to a downregulation of Akt/protein kinase B (Akt), a key intermediate in the phosphatidylinositol 3 (PI3)-kinase arm of the IGF-I signaling pathway. We used two methods to determine the regulation of Akt in response to the pro-apoptotic stimuli of serum deprivation and high glucose stress, as well as treatment with IGF-I. We also looked at the phosphorylatiom state of GSK-3beta at Ser9. Using a kinase assay with immunoprecipitated Akt, we detected an increased Akt activity in PS1 L250S cells at 1 hr after the combination of 20 mM glucose plus 10 nM IGF-I, when compared to the other cell types. This effect, however, was transient in that no mutation related differences were seen at either 6- or 24-hr post-treatment. Immunoblotting for Phospho-Akt as a ratio of total Akt, as well as for GSK-3beta phosphorylated at Ser9 revealed no apparent between cell type and treatment differences. This data strongly indicates that PS1 wt and mutant cells show no major differences in the pattern of Akt regulation after exposure to the pro-apoptotic stimuli of either serum deprivation or high glucose stress, or treatment with IGF-I. It is suggested that another component of IGF-I signaling is likely disrupted in these cells to increase their vulnerability to undergo death by apoptosis. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11746362     DOI: 10.1002/jnr.10006

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  5 in total

1.  Insulin-like growth factor-I mediates neuroprotection in proteasome inhibition-induced cytotoxicity in SH-SY5Y cells.

Authors:  Benxu Cheng; Shivani Kaushal Maffi; Alex Anthony Martinez; Yolanda P Villarreal Acosta; Liza D Morales; James L Roberts
Journal:  Mol Cell Neurosci       Date:  2011-04-23       Impact factor: 4.314

2.  PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations.

Authors:  Lia Baki; Junichi Shioi; Paul Wen; Zhiping Shao; Alexander Schwarzman; Miguel Gama-Sosa; Rachael Neve; Nikolaos K Robakis
Journal:  EMBO J       Date:  2004-06-10       Impact factor: 11.598

3.  Cortical development in the presenilin-1 null mutant mouse fails after splitting of the preplate and is not due to a failure of reelin-dependent signaling.

Authors:  Rita De Gasperi; Miguel A Gama Sosa; Paul H Wen; Jingjun Li; Gissel M Perez; Tom Curran; Gregory A Elder
Journal:  Dev Dyn       Date:  2008-09       Impact factor: 3.780

Review 4.  Cyclin-Dependent Kinase-Like 5 (CDKL5): Possible Cellular Signalling Targets and Involvement in CDKL5 Deficiency Disorder.

Authors:  Syouichi Katayama; Noriyuki Sueyoshi; Tetsuya Inazu; Isamu Kameshita
Journal:  Neural Plast       Date:  2020-06-05       Impact factor: 3.599

5.  Combined Scutellarin and C18H17NO6 Imperils the Survival of Glioma: Partly Associated With the Repression of PSEN1/PI3K-AKT Signaling Axis.

Authors:  Xiu-Ying He; Yang Xu; Qing-Jie Xia; Xiao-Ming Zhao; Shan Li; Xiao-Qiong He; Ru-Rong Wang; Ting-Hua Wang
Journal:  Front Oncol       Date:  2021-09-09       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.